Olympus Co. (OTCMKTS:OCPNY – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $18.00 and traded as low as $18.00. Olympus shares last traded at $18.00, with a volume of 400 shares traded.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group raised Olympus to a “buy” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy”.
Check Out Our Latest Research Report on OCPNY
Olympus Stock Down 1.4%
About Olympus
Olympus Corporation is a Tokyo-headquartered manufacturer specializing in medical and scientific imaging, precision optics and related equipment. The company’s medical systems business is focused on endoscopic technologies and therapeutic devices used in minimally invasive diagnosis and treatment, supplying hospitals and clinical facilities with endoscopes, visualization platforms and accessories. In addition to healthcare, Olympus serves scientific and industrial customers with microscopes, imaging systems, non-destructive testing equipment and precision measurement tools used in research, manufacturing and quality control.
In recent years the company completed a strategic refocus on healthcare and scientific solutions, divesting its consumer camera business in 2020 to concentrate resources on medical device development, services and life-science applications.
Read More
- Five stocks we like better than Olympus
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
